Category

Biotechnology ETFs

What the 3rd Quarter Tells Us About The Stock Market In October

By | Biotechnology ETFs, Bond ETFs, Consumer ETFs, Current Affairs and ETFs, Dividend ETFs, Energy ETFs, ETF Philosophy, ETF Strategy, International ETFs, Large Cap ETFs, Semiconductor ETFs, Special Sectors ETFs, Technology ETFs, US Markets and ETFs, Utilities ETFs | No Comments

Three months ago to the day (6/30), I served up a list of reasons for lowering one’s exposure to riskier assets. I discussed weakness in market internals where fewer and fewer corporate components of the Dow and S&P 500 had been propping up the popular U.S. benchmarks. I talked about the faster rate of deterioration in foreign stocks over domestic stocks via the Vanguard FTSE All-World (VEU):S&P 500 SPDR Trust (SPY) price ratio. Additionally, I highlighted exorbitant U.S. stock valuations,…

Read More

Resilient Consumer? Not During The Manufacturing Retreat and Corporate Revenue Recession

By | Biotechnology ETFs, Bond ETFs, Commodity ETFs, Consumer ETFs, Dividend ETFs, ETF Philosophy, ETF Strategy, Health ETFs, Large Cap ETFs, Small Cap ETFs, US Markets and ETFs | No Comments

Concerned investors started punishing foreign stocks and emerging market equities in May. The primary reason? Many feared the adverse effects of declining economic growth around the globe as well as the related declines in world trade. By June, risk-averse investors began selling U.S. high yield bonds as well as U.S. small cap assets. A significant shift away from lower quality debt issuers troubled yield seekers, particularly in the energy arena. Meanwhile, the overvaluation of smaller companies in the iShares Russell…

Read More

Why The S&P 500 Is Likely To Revisit The Correction Lows Near 1870

By | Asia ETFs, Biotechnology ETFs, Bond ETFs, Consumer ETFs, Current Affairs and ETFs, ETF Philosophy, ETF Strategy, Large Cap ETFs, Mid Cap ETFs, US Markets and ETFs | No Comments

In Selling The Drama Or Buying The Rally (8/27), I delineated the way in which 10%-plus price corrections had unfolded under similar circumstances in history (e.g., 1998, 2010, 2011, etc.). Specifically, when the prospects for the global economy are deteriorating, U.S. stock benchmarks typically reclaim about one-half of their losses on “hope rallies.” Afterwards, they retest their lows. The most recent example of the price movement phenomenon is the euro-zone crisis. In late July/early August of 2011, the S&P 500 SPDR Trust…

Read More

The Stock Market’s Best Shot? A Fed Promise To Move Slower Than A Three-Toed Sloth

By | Asia ETFs, Biotechnology ETFs, Consumer ETFs, Current Affairs and ETFs, Dividend ETFs, Energy ETFs, ETF Philosophy, ETF Strategy, Health ETFs, Industrial ETFs, Large Cap ETFs, Materials ETFs, Mid Cap ETFs, Transportation ETFs, US Markets and ETFs | No Comments

Consumers, as opposed to manufacturers, represent two-thirds of the U.S. economy. Indeed, Americans love to splurge. We buy sneakers, iPhones, home furnishings, real estate, cars, jewelry, concert tickets, and meals at our favorite restaurants. We even buy chew toys for our pets. Many of us, however, do not have enough cash saved up to acquire the things that we want when we want them. So we borrow. We satisfy our cravings through instruments of debt – credit cards, mortgages, “refis,”…

Read More

This Is What Happens When The Fed Tries To Leave ‘QE’

By | Alt Energy ETFs, Biotechnology ETFs, China ETFs, Current Affairs and ETFs, Energy ETFs, ETF Philosophy, ETF Strategy, International ETFs, Large Cap ETFs, Special Sectors ETFs, Technology ETFs, US Markets and ETFs | No Comments

Back on October 29, 2014, the Federal Reserve ended its largest round of quantitative easing (QE3/QE4). The unconventional policy of buying market-based assets with electronically created credits (dollars) first began in late November of 2008. Since that time, $3.75 trillion in stimulus forced interest rates downward and sent stock prices soaring. The S&P 500 moved from 857.39 when QE1 was first announced to 1982.30 when QE3/QE4 ran its course for an approximate gain of 131%. Equally intriguing, when the Fed backed…

Read More

Why Investors Should Not Party Like It’s 1999

By | Biotechnology ETFs, Current Affairs and ETFs, ETF Philosophy, ETF Strategy, Large Cap ETFs, Small Cap ETFs, US Markets and ETFs | No Comments

Tens of thousands of investors read my commentary at popular financial portals. Some have been reading my articles for more than a decade. Others might have clicked on a social media “follow” link in the last month or the last last year. Ironically, few realize that I originally developed a front-n-center persona on national talk radio in the late 1990s. The medium was unique in the way that listeners felt like they had a connection with me (a.k.a. “the G-Man”)…

Read More

The Risk Of Owning Stock Assets and Holding Stock Assets Right Now

By | Biotechnology ETFs, Bond ETFs, Current Affairs and ETFs, Dividend ETFs, ETF Philosophy, ETF Strategy, Health ETFs, Large Cap ETFs, Special Sectors ETFs, US Markets and ETFs | No Comments

Hold-n-hope advocates believe that greater gains with stocks over investment grade bonds require nothing more than a commitment to accepting increased volatility. In other words, if you accept the occasional craziness of stock prices, then your rewards will be far more robust than lower yielding debt instruments. But is that even accurate? In the 15-year period through 5/31/2015, stocks exhibited 4 times the amount of price vacillation (a.k.a. volatility) than bonds. Yet the S&P 500 SPDR Trust (SPY) provided annualized gains…

Read More

Rate-Sensitive, Energy-Sensitive Sectors Now Down 10%-Plus

By | Biotechnology ETFs, Bond ETFs, Current Affairs and ETFs, Dividend ETFs, Energy ETFs, ETF Philosophy, ETF Strategy, Health ETFs, Internet ETFs, Natural Resources ETFs, Real Estate ETFs, Technology ETFs, Transportation ETFs, US Markets and ETFs, Utilities ETFs | No Comments

Bullish borrowers have increased their margin debt to invest in stocks from $445 billion in January to $507 billion today. And why not? The overall price movement for growth sectors of the stock market remains healthy. Flashy sub-segments like cyber-security and biotech continue to soar. For example, I allocated a small portion of moderately aggressive client assets to the Pure Funds ISE Cyber Security ETF (HACK) in early February. Its series of higher lows since its inception lent credibility to…

Read More

‘Taper Tantrum’ Round 2? It’s More Serious For Stocks This Time Around

By | Asia ETFs, Biotechnology ETFs, Bond ETFs, Consumer ETFs, Current Affairs and ETFs, Dividend ETFs, ETF Philosophy, ETF Strategy, Europe ETFs, Global ETFs, International ETFs, Large Cap ETFs, Mid Cap ETFs, US Markets and ETFs | No Comments

By definition, a recovery is the regaining of something lost. Homeowners have partially (and in some instances, entirely) recovered the equity in their property since the start of the Great Recession. Similarly, market-based securities investors have regained their capital and even accumulated additional paper wealth. The jobs recovery is a bit more challenging to quantify. For example, prior to the start of the Great Recession in December of 2007, the headline unemployment rate was 4.7%. A year into the economic contraction,…

Read More

What the NASDAQ’s Round-Trip To 5000 Really Means

By | Biotechnology ETFs, Consumer ETFs, Currency ETFs, Current Affairs and ETFs, Dividend ETFs, ETF Philosophy, ETF Strategy, Health ETFs, International ETFs, Large Cap ETFs, Special Sectors ETFs, Technology ETFs, US Markets and ETFs | No Comments

When the NASDAQ Composite Index hit 5000 in March of 2000, jubilant investors celebrated the milestone. Shortly thereafter, however, scores of individuals lost their collective shirts. Many witnessed losses of 50%, 60% or 80% of their account values on names like Cisco, JDS Uniphase and Pets.com. Back then, the euphoria was akin to unchecked greed. Today, the public is far more subdued. And that’s a positive sign. After all, how could we be in a “stock bubble” if we are…

Read More